Cancer Research AACR Legacy Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Livingstone, M.
Right arrow Articles by Halazonetis, T. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Livingstone, M.
Right arrow Articles by Halazonetis, T. D.
[Cancer Research 65, 7533-7540, September 1, 2005]
© 2005 American Association for Cancer Research

Priority Reports

Valosin-Containing Protein Phosphorylation at Ser784 in Response to DNA Damage

Mark Livingstone1, Hong Ruan1, Jessica Weiner2, Karl R. Clauser2, Peter Strack2, Shengfang Jin2, Amy Williams2, Heidi Greulich2, James Gardner2, Monica Venere3,4, Tamara A. Mochan3,4, Richard A. DiTullio, Jr.3,4, Katarina Moravcevic3,4, Vassilis G. Gorgoulis3, Anne Burkhardt2 and Thanos D. Halazonetis3,5

1 Cell Signaling Technology, Inc., Beverly, Massachusetts; 2 Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts; 3 Wistar Institute; 4 Cell and Molecular Biology and Biochemistry Graduate Groups, Biomedical Graduate Studies; and 5 Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

Requests for reprints: Thanos D. Halazonetis, Wistar Institute, Room 115, Philadelphia, PA 19104. Phone: 215-898-3789; Fax: 215-573-9271; E-mail: halazonetis{at}wistar.upenn.edu.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The response of eukaryotic cells to DNA damage includes the activation of phosphatidylinositol-3 kinase–related kinases (PIKK), such as ATM, ATR, and DNA-dependent protein kinase (DNA-PK). These three kinases have very similar substrate specificities in vitro, but in vivo, their substrates overlap only partially. Several in vivo substrates of ATM and ATR have been identified and almost all of them are involved in DNA damage–induced cell cycle arrest and/or apoptosis. In contrast, few in vivo substrates of DNA-PK have been identified. These include histone H2AX and DNA-PK itself. We identify here valosin-containing protein (VCP) as a novel substrate of DNA-PK and other PIKK family members. VCP is phosphorylated at Ser784 within its COOH terminus, a region previously shown to target VCP to specific intracellular compartments. Furthermore, VCP phosphorylated at Ser784 accumulated at sites of DNA double-strand breaks (DSBs). VCP is a protein chaperone that unfolds and translocates proteins. Its phosphorylation in response to DNA damage and its recruitment to sites of DNA DSBs could indicate a role of VCP in DNA repair.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
The DNA damage checkpoint is an evolutionarily conserved signaling pathway that in response to DNA damage triggers cell cycle arrest and/or apoptosis (1). The key transducers of the DNA damage signal are the protein kinases ATM and ATR, which are activated primarily by DNA double-strand breaks (DSBs) and replication blocks, respectively (2, 3). ATM and ATR are members of the phosphatidylinositol-3 kinase–related kinase (PIKK) family and phosphorylate serine or threonine residues that are followed by a glutamine (4). As such, ATM and ATR are often referred to as S/T-Q-directed kinases. Several in vivo substrates of ATM and ATR have been identified, including Chk2, Chk1, p53, SMC1, histone H2AX, NBS1, BRCA1, and FANCD2 (1–4). Most of these proteins are phosphorylated by ATM and ATR at multiple sites that typically cluster near each other. For example, Chk2 has 7 S/T-Q sites within its NH2 terminus. Of these seven sites, Thr68 is the predominant site phosphorylated by ATM, whereas other sites, such as Ser33, are phosphorylated by ATM only when cells are exposed to high doses of ionizing radiation (5, 6).

DNA-dependent protein kinase (DNA-PK) is a third member of the PIKK family (4). Unlike ATM and ATR, inactivation of DNA-PK does not lead to major cell cycle checkpoint defects but instead compromises nonhomologous end joining (NHEJ)–mediated repair of DNA DSBs (7). DNA-PK phosphorylates many proteins in vitro, but few in vivo substrates have been identified. These include histone H2AX, the Werner syndrome helicase, Artemis, XRCC4, and DNA-PK itself (8–11). DNA-PK autophosphorylation, especially at Thr2609, is important for DNA-PK to stimulate NHEJ (7, 8).

A protein recently proposed to play a role in repair of DNA damage is valosin-containing protein (VCP), a 97-kDa homologue of yeast Cdc48p (12–14). VCP is a ubiquitous and highly abundant ATPase that belongs to the AAA (ATPase associated with a variety of cellular activities) family and assembles as a hexamer forming a ring with a channel at its center (15–17). The VCP homohexamers associate with a number of protein cofactors forming distinct macromolecular complexes, which act as chaperones unfolding target proteins and translocating them to specific cellular compartments or to the proteasome (13). Because VCP can participate in several macromolecular complexes and can act as a chaperone of many proteins, it is involved in many unrelated cellular activities, such as membrane fusion, cell cycle regulation, stress response, programmed cell death, B- and T-cell activation, transcriptional regulation, endoplasmic reticulum (ER)–associated degradation, and protein degradation (13). VCP has also been proposed to play a role in the DNA damage response, because it can associate with the Werner syndrome protein, a member of the RecQ helicase family (18, 19), as well as with BRCA1 (20). However, its precise role in the response of cells to DNA damage is still obscure.

In an effort to identify novel proteins that become phosphorylated at S/T-Q motifs in response to DNA damage, we isolated proteins that cross-react with an antibody raised against a synthetic Chk2 peptide, in which Thr26 and Ser28 of Chk2 were phosphorylated. Surprisingly, the predominant protein recognized by this antibody in cells exposed to DNA-damaging agents was VCP. We mapped the site of VCP phosphorylation at Ser784 and showed that VCP was phosphorylated by multiple PIKK family members. These results suggest that VCP is a direct target of DNA damage signaling pathways in mammalian cells.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Antibodies. The phospho-Chk2 (Thr26/Ser28) antibody was produced as previously described (21) using as antigen a synthetic keyhole limpet hemocyanin–coupled Chk2 phosphopeptide of the sequence QPHGSVtQsQGSS, where t and s mark the phosphorylated threonine and serine, respectively. Immunoglobulins from the immunized rabbits were precipitated by Protein A-Sepharose; phospho-Chk2-reactive antibodies were then affinity purified first by removing antibodies that recognize nonphosphorylated Chk2 and then by selecting for antibodies that recognize phosphorylated Chk2 using columns carrying immobilized nonphosphorylated and phosphorylated Chk2 peptides, respectively. The specificity of the affinity-purified antibodies was confirmed using extracts prepared from untreated and DNA damage–treated cells expressing FLAG-tagged wild-type Chk2 or Chk2 mutated at Thr26/Ser28 (22). All other antibodies used in this study were commercially available or were previously described: VCP monoclonal, Maine Biotechnology Services, Inc., Portland, ME (#MAB696S); DNA-PKcs rabbit polyclonal, Abcam, Cambridge, United Kingdom (#ab230); 53BP1 monoclonal (23); and histone H3 rabbit polyclonal, Abcam (#ab1791).

Cell lines. The following human cell lines were obtained from the American Type Culture Collection (Manassas, VA): HeLa cervical carcinoma, U2OS osteosarcoma, 293 embryonic kidney cells, HCT15 colon carcinoma, M059K (wild-type DNAPK), and M059J (DNA-PK deficient) glioblastomas. AG1522 normal human primary fibroblasts and AT5BI primary fibroblasts from a patient with ataxia-telangiectasia have been described previously (24).

Induction of DNA damage. DNA damage was induced by exposing cells to ionizing radiation (137Cs source), UV light (254 nm; Stratalinker, Stratagene, La Jolla, CA), doxorubicin (0.2 µg/mL for 24 hours; Sigma, St. Louis, MO; #D1515), bleomycin (20 µg/mL for 30 minutes; Sigma, #B8416), or hydroxyurea (1 mmol/L for 8 hours; Sigma, #H8627).

Cell extracts, immunoprecipitation, and immunoblotting. Whole cell protein extracts were prepared from HeLa, 293, M059K, and M059J cells by lysis in buffer containing 50 mmol/L HEPES (pH 7.55), 150 mmol/L NaCl, 1 mmol/L EDTA, 5% glycerol, 1% NP40, 1 mmol/L DTT, 1 mmol/L sodium vanadate, and a protease inhibitor cocktail for 10 minutes on ice followed by centrifugation to remove the particulate material. To prepare chromatin-enriched fractions and matched whole cell extracts, the cells were lysed in buffer consisting of 100 mmol/L Tris-HCl (pH 8.0), 240 mmol/L NaCl, 1% NP40, 1 mmol/L DTT, and protease-kinase-phosphatase inhibitors (6, 23). After centrifugation, the soluble material served as matched whole cell extract, whereas the chromatin-enriched pellet was solubilized by incubation in buffer consisting of 10 mmol/L HEPES, 1.5 mmol/L MgCl2, 10 mmol/L KCl, 0.5 mmol/L DTT, 1.5 mmol/L phenylmethylsulfonyl fluoride, and 0.25 N HCl for 1 hour at 4°C. After being solubilized, the chromatin-enriched fraction was clarified by centrifugation and neutralized by adding one-fifth volume 1.5 mol/L Tris-HCl (pH 8.8). Nuclear extracts were prepared from U2OS cells as previously described (25). Immunoprecipitations were done using 800 µg whole cell extract, 0.4 µg phospho-Chk2 (Thr26/Ser28) antibody and 50 µL Protein G-Agarose beads. For immunoblotting either half of the immunoprecipitated reaction or whole cell extracts (100 µg) or nuclear extracts (25 µg) or chromatin-enriched fractions (15 µg) and matched whole cell extracts (1.5 µg) were resolved on SDS-polyacrylamide gels.

Mass spectrometry. Mass spectrometry (MS) was done using as starting material 800 µg HeLa whole cell extract immunoprecipitated with the phospho-Chk2 (Thr26/Ser28) antibody, as described above, or 3 mg U2OS nuclear extract immunoprecipitated with 10 µg phospho-Chk2 (Thr26/Ser28) antibody that had been covalently coupled to epoxy-dynabeads (Dynal M-270 Epoxy 143.01) according to the instructions of the manufacturer. The immunoprecipitated proteins were resolved on SDS-polyacrylamide gels, stained with colloidal Coomassie blue, and destained with 1% acetic acid and 30% methanol. The bands corresponding to proteins immunoprecipitated from HeLa cells were excised and cut in half; one half was subjected to in-gel proteolytic digestion with trypsin and the other half with chymotrypsin to maximize coverage of the protein by recovered peptides. After quenching the digestions by lowering the pH to ~2 to 3 with acetic acid, the two portions of each band were mixed back together and analyzed by liquid chromatography-coupled tandem MS (LC/MS/MS). The bands corresponding to proteins immunoprecipitated from U2OS cells were treated similarly, except that they were digested only with trypsin. Data-dependent LC/MS/MS was done using electrospray ionization on a Finnigan LCQ ion trap mass spectrometer. An aliquot of each digest mixture was introduced to the mass spectrometer by reversed-phase chromatographic separation with a 75-µm-inner-diameter capillary column flowing at a rate of ~350 nL/min and eluted using a 60-minute acetonitrile/0.1% acetic acid gradient. Chromatographic separation yielded ~30-second peak widths and mass spectra were acquired in 9-second cycles. Each cycle was of the form: one full MS scan followed by four MS/MS scans on the most abundant precursor ions, subject to dynamic exclusion for a period of 1.5 minutes. The identity of each peptide sequenced was determined by interpreting the MS/MS spectra using the SpectrumMill software we have developed (Agilent Technologies, Inc., Santa Clara, CA). Phosphorylated peptides were not detected in this data-dependent mode of operation. To establish the VCP phosphorylation site Ser784, a second LC/MS/MS run was done with the instrument operated in a multiple-reaction monitoring mode where MS/MS of the precursor m/z values 1,120.6 and 1,160.6 were repetitively taken throughout the acetonitrile gradient. These masses were selected because they correspond to the unphosphorylated and phosphorylated forms, respectively, of the chymotryptic VCP peptide RFPSGNQGGAGPsQGSGGGTGGSVY, which contains the region of VCP most similar to the peptide used to raise the phospho-Chk2 (Thr26/Ser28) antibody.

Valosin-containing protein cDNA cloning and plasmid construction. Human VCP cDNA was amplified by PCR from a fetal brain library (Clontech, Palo Alto, CA) and subcloned in the pCMV-Tag2B vector (Stratagene). Ser784 was mutated to alanine using the Stratagene QuickChange mutagenesis kit.

Cell transfection and in vitro DNA-PK kinase reaction. Plasmids expressing FLAG-tagged wild-type or Ser784Ala (S784A) VCP were transiently transfected into exponentially growing 293 cells using Effectene (Qiagen, Inc., Chatsworth, CA). Forty-eight hours after transfection, the medium was replaced with fresh growth medium supplemented with 40 µg/mL bleomycin. Cell lysates were immunoprecipitated overnight with anti-FLAG M2 monoclonal antibody coupled to agarose beads (Sigma, #A-1205). After washing, the beads were resuspended in 150 µL whole cell lysis buffer without sodium vanadate. Then, one third of the beads was saved as untreated control; one third was treated with 5 µL calf intestinal phosphatase (CIP; New England Biolabs, Beverly, MA, #M-0290L); and the other third was treated with CIP, washed, and then incubated with 1 µL DNA-PK (Promega, Madison, WI, #V581A). Proteins bound to the beads were resolved by SDS-PAGE and immunoblotted, as described above.

Small interference RNA transfections. U2OS cells were transfected with luciferase small interference RNA (siRNA) oligonucleotides or siRNA specific for 53BP1 (Dharmacon, Lafayette, CO), as previously described (25). The sequence of the siRNA for 53BP1 was GAACGAGGAGACGGUAAUAdTdT.

Immunofluorescence. Immunofluorescence was done as described previously (25). All immunofluorescence images were processed using the Imagevision Tools Library of IRIX (Silicon Graphics, Mountain View, CA).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
The phospho-Chk2 (Thr26/Ser28) antibody recognizes valosin-containing protein in cells with DNA damage. Immunoblotting of whole cell lysates from doxorubicin-treated HeLa cells, using the phosphoChk2 (Thr26/Ser28) antibody, revealed at least four proteins, whose phosphorylation was induced by DNA damage (Fig. 1A, left). The major protein recognized by the phosphospecific antibody had a molecular weight of 97 kDa, so it could not be Chk2. This 97-kDa protein was the only protein detected in lysates of doxorubicin-treated cells by sequential immunoprecipitation and immunoblotting using the phospho-Chk2 (Thr26/Ser28) antibody (Fig. 1A, middle) and practically the only protein detected by sequential immunoprecipitation and staining of the gel with colloidal Coomassie blue (Fig. 1A, right). To determine its identity, a gel slice containing this protein was treated with proteases and the generated peptides were subjected to LC/MS/MS. The 97-kDa protein was unambiguously identified as the p97 VCP. In addition, two very faint protein bands from the same gel were identified as filamin (~280 kDa) and the catalytic subunit of DNA-PK (~450 kDa; Fig. 1A, right).



View larger version (35K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1. Phospho-Chk2 (Thr26/Ser28) antibody recognizes VCP in cells exposed to DNA-damaging agents. A, whole cell extracts prepared from untreated or doxorubicin (Dox)–treated HeLa cells were immunoblotted (IB), immunoprecipitated and immunoblotted (IP/IB), or immunoprecipitated, resolved by SDS-PAGE, and stained with Coomassie blue (IP/CB), as indicated. pT26S28, phospho-Chk2 (Thr26/Ser28) antibody. Left, molecular weight markers (in kDa); Coomassie blue–stained bands were identified by MS. B, whole cell extracts prepared from untreated or doxorubicin-treated HeLa cells were either immunoblotted, or immunoprecipitated and immunoblotted with antibodies that recognize phospho-Chk2 (Thr26/Ser28; pT26S28), VCP or the catalytic subunit of DNAPK (DNAPKcs), as indicated. C, nuclear extracts prepared from U2OS cells [untreated, irradiated (IR; 3 Gy, 30 minutes), treated with hydroxyurea (HU; 1 mmol/L, 8 hours), or exposed to UV light (50 J/m2, 2 hours)] were either immunoblotted or immunoprecipitated, resolved by SDS-PAGE, and stained with Coomassie blue, as indicated. Coomassie blue–stained bands were identified by MS. nmMyosin, non–muscle myosin heavy chain type A.

 
The identity of VCP and DNA-PK as proteins recognized by the phospho-Chk2 (Thr26/Ser28) antibody in doxorubicin-treated HeLa cells was further verified by sequential immunoprecipitation with the phospho-Chk2 (Thr26/Ser28) antibody and immunoblotting with antibodies specific for VCP or DNA-PK (Fig. 1B). These experiments further indicated that doxorubicin treatment did not affect the overall protein levels of VCP and DNA-PK in HeLa cells.

Having established that VCP is the major protein recognized by the phospho-Chk2 (Thr26/Ser28) antibody in doxorubicin-treated HeLa cells, we subsequently examined U2OS osteosarcoma cells exposed to ionizing radiation, hydroxyurea, or UV light. Immunoblotting of nuclear extracts from these cells revealed a 97-kDa molecular weight protein that reacted with the phospho-Chk2 (Thr26/Ser28) antibody in response to DNA damage (Fig. 1C, left). We then used this same antibody for protein immunoprecipitation and identification of the immunoprecipitated proteins by MS. A single protein was immunoprecipitated from extracts of U2OS cells exposed to ionizing radiation; this protein was identified as VCP by MS (Fig. 1C, right). From extracts of cells exposed to UV light, several proteins were immunoprecipitated; one of these was VCP. The remaining were cytoskeletal proteins, such as gelsolin, drebrin E, {alpha}-actinin 4, and non–muscle myosin heavy chain type A (Fig. 1C, right). These highly abundant cytoskeletal proteins are constitutively phosphorylated and have been previously described as contaminants in immunoprecipitations with phosphospecific antibodies (26). Thus, based on the analysis of HeLa and U2OS cells described above, we conclude that VCP is phosphorylated in response to several DNA-damaging agents and is the predominant protein recognized by the phospho-Chk2 (Thr26/Ser28) antibody. In support of this conclusion, immunoblotting of lysates prepared from multiple other cell lines (HT29, COS7, 293, WI38, MCF7, HCT116, MCF10A, and HCT15) with the phospho-Chk2 (Thr26/Ser28) antibody revealed that the major protein phosphorylated in response to various DNA-damaging agents (doxorubicin, bleomycin, ionizing radiation, UV, and hydroxyurea) had a molecular weight of 97 kDa (data not shown).

Valosin-containing protein is phosphorylated at Ser784 in response to DNA damage. To establish the site of VCP phosphorylation in response to DNA damage, VCP was immunoprecipitated with the phospho-Chk2 (Thr26/Ser28) antibody from doxorubicin-treated HeLa cells, digested with chymotrypsin, and then analyzed by LC/MS/MS. The instrument was operated in a multiple-reaction monitoring mode where MS/MS of the precursor m/z values 1,120.6 and 1,160.6 were repetitively taken throughout the acetonitrile gradient. These masses were selected because they correspond to the unphosphorylated and phosphorylated forms, respectively, of the chymotryptic peptide RFPSGNQGGAGPsQGSGGGTGGSVY, which contains the region of VCP most similar to the peptide used to raise the phospho-Chk2 (Thr26/Ser28) antibody. Interpretation of the spectra of the precursor m/z 1,160.6 unambiguously revealed that Ser784 was phosphorylated (Fig. 2A).



View larger version (28K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 2. VCP is phosphorylated at Ser784 in doxorubicin-treated HeLa cells. A, ion trap LC/MS/MS spectrum of a precursor m/z 1,160.6 VCP chymotryptic peptide. The sequence of the precursor peptide is shown below the LC/MS/MS spectrum (black letters) and potential cleavage points numbered from the NH2-terminal and COOH-terminal ends are indicated above and below the precursor peptide sequence, respectively. The slashes in the peptide sequence between the amino acids indicate cleavage points generated during the MS/MS scans. The precursor mass is consistent with one phosphate in the peptide and the b14/y11 and b11/y14 ions enable the conclusive assignment of Ser13 (Ser784 in the full-length sequence) as the phosphorylated residue. Several ions in the spectrum exhibit the neutral loss of phosphoric acid characteristic of phospho-serine and threonine residues. B, the phospho-Chk2 (Thr26/Ser28) antibody recognizes VCP phosphorylated at Ser784. 293 cells were transfected with plasmids expressing FLAG (FL)–tagged wt or Ser784Ala (S784A) VCP and treated with bleomycin. FLAG-tagged proteins were immunoprecipitated with an antibody that recognizes the FLAG tag and either not treated or treated with phosphatase (PPase) or sequentially with phosphatase and then with DNA-PK, as indicated. The immunoprecipitated proteins were then immunoblotted (IB) with the phospho-Chk2 (Thr26/Ser28) antibody (pT26S28) or with the antibody that recognizes the FLAG tag. C, alignment of the sequence of the synthetic peptide used to generate the phospho-Chk2 (Thr26/Ser28) antibody to the sequence of human VCP surrounding Ser784. Phosphorylated serine and threonine residues (lowercase letters).

 
The identification of Ser784 as a residue phosphorylated in response to DNA damage raises the possibility that the phospho-Chk2 (Thr26/Ser28) antibody recognizes VCP phosphorylated at Ser784. However, it is formally possible that VCP might be phosphorylated at multiple sites in response to DNA damage, in which case a site other than Ser784 might be recognized by the phospho-Chk2 (Thr26/Ser28) antibody. To establish that the phospho-Chk2 (Thr26/Ser28) antibody recognizes VCP phosphorylated at Ser784, we examined whether the phospho-Chk2 (Thr26/Ser28) antibody would recognize a VCP mutant that had Ser784 substituted with alanine (S784A). Human embryonic kidney 293 cells were transfected with wild-type (wt) or S784A mutant FLAG-tagged VCP, the cells were treated with the DNA-damaging agent bleomycin and then the FLAG-tagged VCP proteins were sequentially immunoprecipitated with an antibody that recognizes the FLAG tag and immunoblotted either with the antibody that recognizes the FLAG tag or with the phospho-Chk2 (Thr26/Ser28) antibody. The S784A VCP protein was not recognized by the phospho-Chk2 (Thr26/Ser28) antibody, whereas wt VCP was recognized (Fig. 2B). Thus, the phospho-Chk2 (Thr26/Ser28) antibody recognizes VCP phosphorylated at Ser784, consistent with the similarity in amino acid sequence of VCP surrounding Ser784 to the sequence of the Chk2 peptide used to generate the phospho-Chk2 (Thr26/Ser28) antibody (Fig. 2C).

Ser784 matches the consensus site for phosphorylation by members of the PIKK family (ATM, ATR, and DNA-PK; ref. 4). To examine whether PIKKs can phosphorylate VCP at Ser784 in vitro, the immunoprecipitated FLAG-tagged wt and S784A VCP proteins were first treated with a phosphatase to dephosphorylate Ser784 and then with DNA-PK. DNA-PK phosphorylated wt VCP in vitro at Ser784 as ascertained by immunoblotting with the phospho-Chk2 (Thr26/Ser28) antibody, whereas no phosphorylation at Ser784 was evident on the S784A mutant, as expected (Fig. 2B). Thus, DNA-PK can phosphorylate VCP in vitro at Ser784.

Multiple phosphatidylinositol-3 kinase–related kinases phosphorylate valosin-containing protein in vivo. The PIKK family members ATM, ATR, and DNA-PK have overlapping substrate specificities in vitro and often phosphorylate the same substrates in vivo (1–4). Yet, these kinases differ in terms of activation kinetics and the DNA-damaging agents they respond to. ATM and DNA-PK respond primarily to DNA DSBs and are activated rapidly after induction of the damage. ATR responds primarily to replication blocks induced by UV light or various chemical inhibitors and the kinetics of activation are slow, reflecting the time it takes for the replication machinery to encounter the damage (2, 3).

As a first step in examining which PIKK family members phosphorylate VCP in vivo, we studied VCP phosphorylation in M059J glioblastoma cells, which express mutant DNA-PK and ATM, and in M059K cells, which are derived from the same patient, but have wt DNA-PK and ATM (27). Both cell lines contained similar levels of VCP. After exposure to bleomycin, which causes DNA DSBs, VCP was phosphorylated at Ser784 in both cell lines. However, at the early time points (15 and 30 minutes) after bleomycin treatment, VCP phosphorylation was compromised in the M059J cells (Fig. 3A and B). The robust phosphorylation of VCP in M059K cells could be inhibited by wortmannin (Fig. 3A), a known inhibitor of PIKK family members (28). Taken together, these results suggest that DNA-PK and/or ATM phosphorylate VCP in vivo at early time points after DNA damage, whereas at later time points, another kinase, probably ATR, phosphorylates VCP.



View larger version (50K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 3. Multiple PIKK family members phosphorylate VCP in vivo. A-C, DNA-PK-deficient M059J and matched DNA-PK-wt M059K cells were exposed to bleomycin (Bleo, 20 µg/mL, 30 minutes in panel A, as indicated in panel B) or UV light (50 J/m2) in the presence or absence of wortmannin (Wortm, 20 µmol/L). Extracts from these cells were immunoblotted (IB) with the phospho-Chk2 (Thr26/Ser28) antibody (pT26S28) or with antibodies that recognize VCP or actin.

 
A potential role of ATR in phosphorylating VCP at Ser784 was examined by exposing M059J and M059K cells to UV light. In both cell lines, VCP was phosphorylated at Ser784 in response to UV light (Fig. 3C). Based on the kinetics of VCP phosphorylation and the presence of mutant DNA-PK and ATM in M059J cells, we conclude that ATR is the likely kinase phosphorylating VCP in cells exposed to UV light.

Valosin-containing protein phosphorylated at Ser784 localizes at sites of DNA double-strand breaks. In cell extracts, the major protein recognized by the phospho-Chk2 (Thr26/Ser28) antibody after induction of DNA damage was VCP (Fig. 1). We used this same antibody to study by immunofluorescence the intracellular localization of VCP phosphorylated at Ser784. In nonirradiated U2OS osteosarcoma cells, the immunofluorescence signal generated by the phosphoChk2 (Thr26/Ser28) antibody was very weak, but after irradiation, the signal was intense and corresponded to foci that colocalized with the ionizing radiation–induced 53BP1 foci (Fig. 4A). These results suggested that VCP phosphorylated at Ser784 localizes at sites of DNA DSBs. Several additional observations support this conclusion.



View larger version (27K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 4. Phospho-Chk2 (Thr26/Ser28) antibody (pT26S28) recognizes phosphorylated VCP at sites of DNA DSBs. A, colocalization of epitopes recognized by the phospho-Chk2 (Thr26/Ser28) antibody with 53BP1 foci in irradiated U2OS cells. Blue circles, computer-generated outlines of 4',6-diamidino-2-phenylindole-stained nuclei. B, Chk2 is not the predominant protein recognized by the phospho-Chk2 (Thr26/Ser28) antibody by immunofluorescence. Foci recognized by the phospho-Chk2 (Thr26/Ser28) antibody develop normally in irradiated HCT15 colon carcinoma cells, although these cells express a mutant form of Chk2 that is not activated in response to irradiation. C, ATM dependence of phospho-Chk2 (Thr26/Ser28) antibody reactivity at early but not late time points after irradiation. Normal diploid fibroblasts (AG1522) and fibroblasts from a patient with ataxia-telangiectasia (AT5BI) were examined 30 minutes or 8 hours after irradiation. D, 53BP1 dependence of phospho-Chk2 (Thr26/Ser28) antibody reactivity in irradiated cells. 53BP1 expression was suppressed by siRNA in U2OS cells. Only the one cell in the image that retains 53BP1 expression shows foci reactive with the phospho-Chk2 (Thr26/Ser28) antibody.

 
First, we showed that the immunofluorescence signal was not due to phosphorylated Chk2. In HCT15 colon carcinoma cells, which express a mutant Chk2 protein that does not become phosphorylated in response to DNA damage (25, 29), the immunofluorescence signal was as robust as in U2OS cells (Fig. 4B), consistent with the phospho-Chk2 (Thr26/Ser28) antibody recognizing primarily phosphorylated VCP.

Second, under a variety of conditions, the immunofluorescence signal correlated well with VCP phosphorylation at Ser784 as monitored by immunoblotting. For example, by immunoblotting, VCP phosphorylation at Ser784 was dependent on ATM at early but not late time points after irradiation (Figs. 1 and 3; data not shown). Immunofluorescence analysis of irradiated and nonirradiated primary fibroblasts from a normal individual (AG1522) and from a patient with ataxia-telangiectasia (AT5BI) indicated reactivity with the phospho-Chk2 (Thr26/Ser28) antibody at both early (30 minutes) and late (8 hours) time points after irradiation in the normal fibroblasts but only at the late time point in ataxia-telangiectasia cells (Fig. 4C).

Third, phosphorylation of VCP, as phosphorylation of many ATM substrates at sites of DNA DSBs (6, 25), was dependent on 53BP1 (6, 25). After suppression of 53BP1 expression by siRNA, immunofluorescence analysis indicated that VCP phosphorylation was also suppressed (Fig. 4D).

The strongest evidence that VCP phosphorylated at Ser784 was present at sites of DNA DSBs came from immunoblotting analysis of chromatin-enriched fractions from untreated and irradiated U2OS cells (Fig. 5). Proteins that localize at sites of DNA DSBs are typically present in the nucleoplasm in untreated cells; but after DNA damage, a certain fraction of the protein is associated with chromatin. We therefore prepared chromatin-enriched fractions and matched whole cell extracts from nonirradiated and irradiated U2OS cells and monitored VCP subcellular localization and phosphorylation at Ser784 by immunoblotting (Fig. 5). VCP was present in the chromatin-enriched fraction after irradiation. Furthermore, the chromatin-enriched fraction, whose quality was verified by immunoblotting for histone H3, contained the majority of VCP phosphorylated at Ser784. Taken together with the immunofluorescence analysis, these data suggest that VCP phosphorylated at Ser784 is present at sites of DNA DSBs.



View larger version (41K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 5. VCP phosphorylated at Ser784 is present in association with chromatin in irradiated cells. Whole cell extracts (WCE) and chromatin-enriched fractions (ChromF) were prepared from nonirradiated (0 Gy) or irradiated (10 or 20 Gy) U2OS cells 15 minutes after irradiation and immunoblotted with the phospho-Chk2 Thr26/Ser28 (pT26S28) antibody or antibodies that recognize VCP or histone H3. Unlike the experiments shown in Figs. 1 and 3, phosphorylated VCP was not detected in the whole cell extracts in this experiment, because 70-fold less extract was used per lane.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
We have identified VCP as a new substrate of PIKK family members in cells exposed to DNA-damaging agents. Furthermore, we have mapped the site of phosphorylation as Ser784. These findings suggest a role of VCP in the cellular response to DNA damage and are consistent with previously published interactions of VCP with BRCA1 and the WRN helicase (18–20).

The precise role of VCP in the DNA damage response remains to be elucidated. VCP has multiple activities in eukaryotic cells (13). The common underlying theme for all these activities is the biochemical function of VCP as a chaperone that can unfold and refold proteins. Many of the activities of VCP involve interactions with polyubiquitinated proteins that VCP unfolds and delivers to the proteasome for degradation (30–33). Other activities of VCP involve unfolding of mono-or nonubiquitinated proteins, which are then delivered to specific subcellular compartments, such as the ER. By analogy, the role of VCP in the DNA damage response may involve unfolding and removing ubiquitinated proteins from sites of DNA damage. Indeed, the response of cells to DNA damage involves several ubiquitination events. Post-replication repair is mediated by the ubiquitin ligases Rad5 and Rad18, which ubiquitinate proliferating cell nuclear antigen (34–36), whereas the response of cells to DNA inter-strand cross-links involves ubiquitination of FANCD2 (37). Furthermore, the DNA damage checkpoint protein BRCA1, which has been reported to interact with VCP (20), is a ubiquitin ligase, although its physiologic substrates have not been identified (38, 39). Thus, it is possible that VCP functions together with ubiquitin ligases at sites of DNA damage. The ubiquitin ligases might modify proteins that VCP would subsequently unfold and channel away from the site of DNA damage.

According to this model, the significance of VCP phosphorylation at Ser784 might be to target VCP at sites of DNA breaks. The specific cellular activity in which a specific VCP molecule participates depends in part on its intracellular localization, which in turn is regulated by COOH-terminal posttranslational modifications (40, 41). For example, phosphorylation of Tyr805 targets VCP to the ER (40). By analogy, phosphorylation of Ser784 may target VCP to sites of DNA damage.


   Acknowledgments
 
Grant support: American Cancer Society grant RPG-96-110-06-GMC (T.D. Halazonetis) and National Cancer Institute grants CA09677 and CA09171 (M. Venere and T.A. Mochan).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank the Wistar Institute Proteomics Facility for the mass spectrometry analysis of the proteins that were immunoprecipitated from U2OS cell extracts.


   Footnotes
 
Note: M. Livingstone is currently at the Department of Biochemistry, McGill University, Montreal, Quebec H3G1Y6, Canada.

K.R. Clauser is currently at the Broad Institute of MIT and Harvard, 320 Bent St., Cambridge, MA 02141.

Received 10/16/04. Revised 5/16/05. Accepted 6/17/05.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Lukas J, Lukas C, Bartek J. Mammalian cell cycle checkpoints: signalling pathways and their organization in space and time. DNA Repair (Amst) 2004;3:997–1007.
  2. Kurz EU, Lees-Miller SP. DNA damage-induced activation of ATM and ATM-dependent signaling pathways. DNA Repair (Amst) 2004;3:889–900.
  3. Shechter D, Costanzo V, Gautier J. Regulation of DNA replication by ATR: signaling in response to DNA intermediates. DNA Repair (Amst) 2004;3:901–8.
  4. Abraham RT. PI 3-kinase related kinases: ‘big’ players in stress-induced signaling pathways. DNA Repair (Amst) 2004;3:883–7.
  5. Ahn J, Urist M, Prives C. The Chk2 protein kinase. DNA Repair (Amst) 2004;3:1039–47.
  6. Mochan TA, Venere M, DiTullio RA, Halazonetis TD. 53BP1 and NFBD1/MDC1-Nbs1function in parallel interacting pathways activating ataxia-telangiectasia mutated (ATM) in response to DNA damage. Cancer Res 2003;63:8586–91.[Abstract/Free Full Text]
  7. Burma S, Chen DJ. Role of DNA-PK in the cellular response to DNA double-strand breaks. DNA Repair (Amst) 2004;3:909–18.
  8. Chan DW, Chen BP, Prithivirajsingh S, et al. Autophosphorylation of the DNA-dependent protein kinase catalytic subunit is required for rejoining of DNA double-strand breaks. Genes Dev 2002;16:2333–8.[Abstract/Free Full Text]
  9. Yannone SM, Roy S, Chan DW, et al. Werner syndrome protein is regulated and phosphorylated by DNA-dependent protein kinase. J Biol Chem 2001;276:38242–8.[Abstract/Free Full Text]
  10. Karmakar P, Piotrowski J, Brosh RM, et al. Werner protein is a target of DNA-dependent protein kinase in vivo and in vitro, and its catalytic activities are regulated by phosphorylation. J Biol Chem 2002;277:18291–302.[Abstract/Free Full Text]
  11. Stiff T, O'Driscoll M, Rief N, Iwabuchi K, Lobrich M, Jeggo PA. ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res 2004;64:2390–6.[Abstract/Free Full Text]
  12. Koller KJ, Brownstein MJ. Use of a cDNA clone to identify a supposed precursor protein containing valosin. Nature 1987;325:542–5.[CrossRef][Medline]
  13. Wang Q, Song C, Li CC. Molecular perspectives on p97-VCP: progress in understanding its structure and diverse biological functions. J Struct Biol 2004;146:44–57.[CrossRef][Medline]
  14. Frohlich KU, Fries HW, Rudiger M, Erdmann R, Botstein D, Mecke D. Yeast cell cycle protein CDC48p shows full-length homology to the mammalian protein VCP and is a member of a protein family involved in secretion, peroxisome formation, and gene expression. J Cell Biol 1991;114:443–53.[Abstract/Free Full Text]
  15. DeLaBarre B, Brunger AT. Complete structure of p97/valosin-containing protein reveals communication between nucleotide domains. Nat Struct Biol 2003;10:856–63.[CrossRef][Medline]
  16. Huyton T, Pye VE, Briggs LC, et al. Freemont PS. The crystal structure of murine p97/VCP at 3.6A. J Struct Biol 2003;144:337–48.[CrossRef][Medline]
  17. Dreveny I, Kondo H, Uchiyama K, Shaw A, Zhang X, Freemont PS. Structural basis of the interaction between the AAA ATPase p97/VCP and its adaptor protein p47. EMBO J 2004;23:1030–9.[CrossRef][Medline]
  18. Partridge JJ, Lopreiato JO, Latterich M, Indig FE. DNA damage modulates nucleolar interaction of the Werner protein with the AAA ATPase p97/VCP. Mol Biol Cell 2003;14:4221–9.[Abstract/Free Full Text]
  19. Indig FE, Partridge JJ, von Kobbe C, Aladjem MI, Latterich M, Bohr VA. Werner syndrome protein directly binds to the AAA ATPase p97/VCP in an ATP-dependent fashion. J Struct Biol 2004;146:251–9.[CrossRef][Medline]
  20. Zhang H, Wang Q, Kajino K, Greene MI. VCP, a weak ATPase involved in multiple cellular events, interacts physically with BRCA1 in the nucleus of living cells. DNA Cell Biol 2000;19:253–63.[CrossRef][Medline]
  21. Weng QP, Kozlowski M, Belham C, Zhang A, Comb MJ, Avruch J. Regulation of the p70 S6 kinase by phosphorylation in vivo. Analysis using site-specific anti-phosphopeptide antibodies. J Biol Chem 1998;273:16621–9.[Abstract/Free Full Text]
  22. Chehab NH, Malikzay A, Appel M, Halazonetis TD. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev 2000;14:278–88.[Abstract/Free Full Text]
  23. Schultz LB, Chehab NH, Malikzay A, Halazonetis TD. p53 binding protein 1 (53BP1) is an early participant in the cellular response to DNA double-strand breaks. J Cell Biol 2000;151:1381–90.[Abstract/Free Full Text]
  24. Waterman MJ, Stavridi ES, Waterman JL, Halazonetis TD. ATM-dependent activation of p53 involves dephosphorylation and association with 14–3-3 proteins. Nat Genet 1998;19:175–8.[CrossRef][Medline]
  25. DiTullio RA, Mochan TA, Venere M, et al. 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nat Cell Biol 2002;4:998–1002.[CrossRef][Medline]
  26. Gronborg M, Kristiansen TZ, Stensballe A, et al. A mass spectrometry-based proteomic approach for identification of serine/threonine-phosphorylated proteins by enrichment with phospho-specific antibodies: identification of a novel protein, Frigg, as a protein kinase A substrate. Mol Cell Proteomics 2002;1:517–27.[Abstract/Free Full Text]
  27. Tsuchida R, Yamada T, Takagi M, et al. Detection of ATM gene mutation in human glioma cell line M059J by a rapid frameshift/stop codon assay in yeast. Radiat Res 2002;158:195–201.[Medline]
  28. Sarkaria JN, Tibbetts RS, Busby EC, Kennedy AP, Hill DE, Abraham RT. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res 1998;58:4375–82.[Abstract/Free Full Text]
  29. Falck J, Lukas C, Protopopova M, Lukas J, Selivanova G, Bartek J. Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway. Oncogene 2001;20:5503–10.[CrossRef][Medline]
  30. Dai RM, Chen E, Longo DL, Gorbea CM, Li CC. Involvement of valosin-containing protein, an ATPase co-purified with I{kappa}B{alpha} and 26 S proteasome, in ubiquitin-proteasome-mediated degradation of I{kappa}B{alpha}. J Biol Chem 1998;273:3562–73.[Abstract/Free Full Text]
  31. Dai RM, Li CC. Valosin-containing protein is a multi-ubiquitin chain-targeting factor required in ubiquitin-proteasome degradation. Nat Cell Biol 2001;3:740–4.[CrossRef][Medline]
  32. Wojcik C. VCP: the missing link in protein degradation? Trends Cell Biol 2002;12:212.
  33. Wojcik C, Yano M, DeMartino GN. RNA interference of valosin-containing protein (VCP/p97) reveals multiple cellular roles linked to ubiquitin/proteasome-dependent proteolysis. J Cell Sci 2004;117:281–92.[Abstract/Free Full Text]
  34. Broomfield S, Hryciw T, Xiao W. DNA postreplication repair and mutagenesis in Saccharomyces cerevisiae. Mutat Res 2001;486:167–84.[Medline]
  35. Torres-Ramos CA, Prakash S, Prakash L. Requirement of RAD5 and MMS2 for postreplication repair of UV-damaged DNA in Saccharomyces cerevisiae. Mol Cell Biol 2002;22:2419–26.[Abstract/Free Full Text]
  36. Hoege C, Pfander B, Moldovan GL, Pyrowolakis G, Jentsch S. RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature 2002;419:135–41.[CrossRef][Medline]
  37. Wang X, D'Andrea AD. The interplay of Fanconi anemia proteins in the DNA damage response. DNA Repair (Amst) 2004;3:1063–9.
  38. Lorick KL, Jensen JP, Fang S, Ong AM, Hatakeyama S, Weissman AM. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc Natl Acad Sci U S A 1999;96:11364–9.[Abstract/Free Full Text]
  39. Ting NS, Lee WH. The DNA double-strand break response pathway: becoming more BRCAish than ever. DNA Repair (Amst) 2004;3:935–44.
  40. Lavoie C, Chevet E, Roy L, et al. Tyrosine phosphorylation of p97 regulates transitional endoplasmic reticulum assembly in vitro. Proc Natl Acad Sci U S A 2000;97:13637–42.[Abstract/Free Full Text]
  41. Madeo F, Schlauer J, Zischka H, Mecke D, Frohlich KU. Tyrosine phosphorylation regulates cell cycle-dependent nuclear localization of Cdc48p. Mol Biol Cell 1998;9:131–41.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
M. A. Gitcho, J. Strider, D. Carter, L. Taylor-Reinwald, M. S. Forman, A. M. Goate, and N. J. Cairns
VCP Mutations Causing Frontotemporal Lobar Degeneration Disrupt Localization of TDP-43 and Induce Cell Death
J. Biol. Chem., May 1, 2009; 284(18): 12384 - 12398.
[Abstract] [Full Text] [PDF]

Home page
 GENES CELLSHome page
C. Mori-Konya, N. Kato, R. Maeda, K. Yasuda, N. Higashimae, M. Noguchi, M. Koike, Y. Kimura, H. Ohizumi, S. Hori, et al.
p97/valosin-containing protein (VCP) is highly modulated by phosphorylation and acetylation.
Genes Cells, April 1, 2009; 14(4): 483 - 497.
[Abstract] [Full Text] [PDF]

Home page
 J. Bacteriol.Home page
P. A. Kirkland, M. A. Gil, I. M. Karadzic, and J. A. Maupin-Furlow
Genetic and Proteomic Analyses of a Proteasome-Activating Nucleotidase A Mutant of the Haloarchaeon Haloferax volcanii
J. Bacteriol., January 1, 2008; 190(1): 193 - 205.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. P. Stokes, J. Rush, J. MacNeill, J. M. Ren, K. Sprott, J. Nardone, V. Yang, S. A. Beausoleil, S. P. Gygi, M. Livingstone, et al.
Profiling of UV-induced ATM/ATR signaling pathways
PNAS, December 11, 2007; 104(50): 19855 - 19860.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J.-J. Mu, Y. Wang, H. Luo, M. Leng, J. Zhang, T. Yang, D. Besusso, S. Y. Jung, and J. Qin
A Proteomic Analysis of Ataxia Telangiectasia-mutated (ATM)/ATM-Rad3-related (ATR) Substrates Identifies the Ubiquitin-Proteasome System as a Regulator for DNA Damage Checkpoints
J. Biol. Chem., June 15, 2007; 282(24): 17330 - 17334.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. Zhao, X. Zhou, L. Wang, G. Li, H. Schindelin, and W. J. Lennarz
Studies on peptide:N-glycanase-p97 interaction suggest that p97 phosphorylation modulates endoplasmic reticulum-associated degradation
PNAS, May 22, 2007; 104(21): 8785 - 8790.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Shi, G. E. Dodson, P. S. Mukhopadhyay, N. P. Shanware, A. T. Trinh, and R. S. Tibbetts
Identification of Carboxyl-terminal MCM3 Phosphorylation Sites Using Polyreactive Phosphospecific Antibodies
J. Biol. Chem., March 23, 2007; 282(12): 9236 - 9243.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
E. G. Mimnaugh, W. Xu, M. Vos, X. Yuan, and L. Neckers
Endoplasmic Reticulum Vacuolization and Valosin-Containing Protein Relocalization Result from Simultaneous Hsp90 Inhibition by Geldanamycin and Proteasome Inhibition by Velcade
Mol. Cancer Res., September 1, 2006; 4(9): 667 - 681.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. L. Rocnik, R. Okabe, J.-C. Yu, B. H. Lee, N. Giese, D. P. Schenkein, and D. G. Gilliland
Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD
Blood, August 15, 2006; 108(4): 1339 - 1345.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Livingstone, M.
Right arrow Articles by Halazonetis, T. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Livingstone, M.
Right arrow Articles by Halazonetis, T. D.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online